Plasma Derived Therapy Market Size by Product (Immunoglobulin, Albumin, Factor VIII, Factor IX), By Application (Hemophilia, Primary Immunodeficiency Disorder), By End User (Hospitals, Clinics), By Geographic Scope and Forecast

Plasma Derived Therapy Market Size and Forecast

The Plasma Derived Therapy Market size was valued at USD 28.12 Billion in 2024 and is projected to reach USD 43.91 Billion in 2031, at a CAGR of 6.32% over the forecast period of 2024 to 2031.

• Plasma derived therapies are biopharmaceutical products manufactured from human plasma, which contains various proteins and antibodies. These therapies are used to treat a wide range of rare and chronic diseases, including hemophilia, primary immunodeficiency disorders, and autoimmune diseases.
• Plasma derived therapies offer life-saving treatment options for patients with rare diseases who have limited or no alternative treatments available. They help replace missing or deficient proteins, enhance the immune system, and control bleeding disorders.
• Plasma-derived therapies are expected to develop alongside personalized medicine, providing focused treatments for uncommon diseases and immunological disorders. They may also experiment with regenerative medicine applications, promoting wound healing and tissue repair and maybe expanding to neurological diseases for greater therapeutic effects.

Global Plasma Derived Therapy Market Dynamics

The key market dynamics shaping the global plasma derived therapy market include

Key Market Drivers

• Growing Prevalence of Rare DiseasesThe increasing prevalence of rare diseases, such as primary immunodeficiency disorders, hemophilia, and autoimmune diseases, is driving the demand for plasma derived therapies as essential treatment options.
• Aging PopulationThe growing geriatric population worldwide is contributing to the rising incidence of age-related diseases, leading to a higher demand for plasma derived therapies to manage these conditions effectively.
• Advancements in Plasma Collection and FractionationTechnological advancements in plasma collection, such as automated plasmapheresis systems and improved fractionation techniques, are enabling more efficient and safer production of plasma derived therapies.
• Rising Awareness and DiagnosisIncreasing awareness about rare diseases and improved diagnostic capabilities are leading to earlier detection and treatment initiation, driving the demand for plasma derived therapies.
• Favorable Reimbursement PoliciesSupportive reimbursement policies and government initiatives for rare disease treatments are improving access to plasma derived therapies and driving market growth.

Key Challenges

• High Treatment Costs The high cost of plasma derived therapies, due to the complex manufacturing process and limited availability of plasma, poses a significant challenge for patient access and affordability.
• Stringent Regulatory Requirements Stringent regulatory guidelines for plasma collection, testing, and manufacturing, along with lengthy approval processes, can delay product launches and impact market growth.
• Limited Plasma Availability The limited availability of plasma donors and potential supply constraints can affect the production and availability of plasma derived therapies, particularly during times of increased demand.
• Risk of Transmission of Infectious Diseases The potential risk of transmission of blood-borne infections during plasma donation and processing requires strict screening and testing procedures, adding to the complexity and cost of production.
• Competition from Alternative Treatments The emergence of alternative treatments, such as recombinant proteins and gene therapies, may pose a competitive threat to plasma derived therapies in certain indications.

Key Trends

• Shift Towards Subcutaneous Administration There is a growing trend towards the development and adoption of subcutaneous immunoglobulin (SCIG) formulations, which offer improved patient convenience and home-based administration options.
• Expansion of Indications Plasma derived therapy manufacturers are exploring new indications and expanding the use of existing therapies to treat a wider range of rare diseases and conditions.
• Focus on Orphan Drugs Pharmaceutical companies are increasingly focusing on the development of plasma derived therapies for orphan diseases, leveraging regulatory incentives and expedited approval pathways.
• Collaborations and Partnerships There is a trend towards collaborations and partnerships between plasma fractionators, biotech companies, and academic institutions to accelerate the development and commercialization of novel plasma derived therapies.
• Adoption of Advanced Manufacturing Technologies Manufacturers are investing in advanced technologies, such as automation, single-use systems and continuous manufacturing, to improve efficiency, scalability, and quality of plasma derived therapies.

Global Plasma Derived Therapy Market Regional Analysis

Here is a more detailed regional analysis of the global plasma derived therapy market

North America

• According to Market Research, North America is expected to dominate the plasma derived therapies market.
• North America is the largest market for plasma derived therapies, driven by a well-established healthcare infrastructure, high diagnosis and treatment rates for rare diseases, and favorable reimbursement policies.
• The U.S. is the dominant player in the region, with a significant number of plasma collection centers and major plasma fractionation companies.
• Canada is also witnessing steady growth in the plasma derived therapy market, supported by government initiatives, and increasing awareness of rare diseases.

Asia Pacific

• According to Market Research, Asia Pacific is fastest growing region in plasma derived therapy market.
• The Asia Pacific region is expected to witness the highest growth rate in the plasma derived therapy market, driven by increasing healthcare expenditure, improving diagnostic capabilities, and rising awareness of rare diseases.
• Countries like China, Japan, and Australia are investing in plasma collection infrastructure and collaborating with global plasma fractionators to meet the growing demand for plasma derived therapies.
• India is also emerging as a significant market, with a large patient population and government initiatives to improve access to rare disease treatments.

Global Plasma Derived Therapy Market Segmentation Analysis

The Global Plasma Derived Therapy Market is segmented based on Product, Application, End User and Geography.

Plasma Derived Therapy Market, By Product

• Immunoglobulin
• Albumin
• Factor VIII
• Factor IX

Based on Product, the market is segmented into Immunoglobulin, Albumin, Factor VIII, Factor IX. Immunoglobulin dominates the market, as it is widely used for the treatment of primary immunodeficiency disorders, autoimmune diseases, and neurological disorders. Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are the main types of immunoglobulin products. Albumin is another significant product segment, used for the treatment of shock, burns, and hypoalbuminemia. Factor VIII and Factor IX are essential for the treatment of hemophilia A and B, respectively, helping to control bleeding episodes and prevent complications.

Plasma Derived Therapy Market, By Application

• Hemophilia
• Primary Immunodeficiency Disorder
• Idiopathic Thrombocytopenic Purpura

Based on Application, the market is segmented into Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura. Hemophilia is a major application area for plasma derived therapies, particularly Factor VIII and Factor IX concentrates, which are crucial for the management of bleeding disorders. Primary Immunodeficiency Disorder is another significant application, where immunoglobulin replacement therapy is used to boost the immune system and prevent infections. Idiopathic Thrombocytopenic Purpura is an autoimmune disorder treated with immunoglobulin and other plasma derived products to increase platelet counts and reduce bleeding risk.

Plasma Derived Therapy Market, By End User

• Hospitals
• Clinics

Based on End User, the market is segmented into Hospitals and Clinics. Hospitals are the primary end users of plasma derived therapies, as they have the necessary infrastructure, specialists and facilities to diagnose and treat rare diseases. Inpatient and outpatient hospital settings are crucial for the administration of plasma derived therapies, particularly for conditions requiring high doses or frequent infusions. Clinics, including specialized rare disease clinics and infusion centers also play a significant role in the delivery of plasma derived therapies, offering convenient and accessible treatment options for patients.

Plasma Derived Therapy Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Geographically, the Global Plasma Derived Therapy Market is classified into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America and Europe are the leading markets, driven by well-established healthcare systems, high awareness of rare diseases, and favorable reimbursement policies. The Asia Pacific region is expected to witness the highest growth rate, fueled by increasing healthcare expenditure, improving diagnostic capabilities, and rising awareness of plasma derived therapies. Latin America and the Middle East and Africa are emerging markets, with a focus on expanding access to rare disease treatments and strengthening healthcare infrastructure.

Key Players

The “Global Plasma Derived Therapy Market” study report will provide valuable insights with an emphasis on the global market including some of the major players such as Grifols, S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A., Biotest AG, Bio Products Laboratory Ltd., LFB S.A., Sanquin, China Biologic Products Holdings, Inc.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

Plasma Derived Therapy Market Recent Developments

• In March 2023, Grifols completed the acquisition of Biotest AG, a German pharmaceutical company specializing in plasma derived therapies. This acquisition strengthened Grifols’ global presence and expanded its product portfolio in the plasma derived therapy market.
• In July 2023, CSL Limited announced the launch of Hizentra, a subcutaneous immunoglobulin (SCIG) therapy, in Japan. This launch expanded CSL’s presence in the Asia Pacific region and provided a convenient treatment option for patients with primary immunodeficiency disorders.
• In August 2023, Takeda Pharmaceutical Company Limited received FDA approval for its plasma derived therapy, TAK-620, for the treatment of hereditary angioedema (HAE). This approval expanded Takeda’s portfolio of rare disease treatments and strengthened its position in the plasma derived therapy market.
• In June 2023, Octapharma AG entered into a collaboration agreement with Cytovant Sciences to develop and commercialize plasma derived therapies for the treatment of COVID-19. This collaboration aimed to leverage Octapharma’s expertise in plasma fractionation to develop potential treatments for the pandemic.
• In September 2023, Kedrion S.p.A. launched a new plasma collection center in the United States, expanding its plasma collection network and ensuring a reliable supply of plasma for the production of its therapies.
• In April 2023, Biotest AG received European Medicines Agency (EMA) approval for its plasma derived therapy, Intratect, for the treatment of primary immunodeficiency disorders. This approval strengthened Biotest’s presence in the European market and expanded treatment options for patients.
• In October 2023, China Biologic Products Holdings, Inc. completed the construction of a new plasma fractionation facility in China. This facility increased China Biologic’s production capacity and positioned the company to meet the growing demand for plasma derived therapies in the Asia Pacific region.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.